In a multicenter, retrospective case series investigation, encorafenib plus binimetinib combination treatment of 24 patients with BRAF-mutant metastatic melanoma BMs resulted in IC ORR of 33% and ORR of 21%101. Here, BRAF is linked to metastatic melanoma.